About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« Abbott Files Reply Brief in Therasense Case | Main | Clinical Trial Requirements Are Top Issue at FDA Hearings on Biosimilars »

November 09, 2010



Your link at the top of the article is actually to the IPO brief.



Thanks for alerting us to the error. The link has been fixed.


The patentability of genes is certainly an interesting topic. I'm not convinced, however, that any definitive legal answer to this conundrum will be forthcoming very soon. Although Myriad is practically guaranteed to go up to the SCOTUS, if the fate of Bilski serves as any example, the Court may merely issue a general (and perhaps even confusing) proclamation, then kick this issue back down to the lower courts, leaving it for them to wrestle with the details.

The comments to this entry are closed.

July 2024

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31